CI

At a glance

ClinicalIndex Comparison Record
Phase 2Completed· 21 enrolled
Drug / intervention
Mesenchymal stem cells +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT01606215
NCT01606215Phase 2Completed
CompareCT.gov

Stem Cells in Rapidly Evolving Active Multiple Sclerosis

Imperial College London·interventional·Posted May 25, 2012·Updated Jan 14, 2025

In Brief

A Phase 2 clinical trial evaluating Mesenchymal stem cells and Placebo for Multiple Sclerosis. Completed, enrolled 21 participants across 1 site.

Detailed Summary

This is a randomised, double-blind crossover study to study the effect of intravenous treatment with autologous (derived from the individuals themselves) mesenchymal stem cells (MSCs) in patients with multiple sclerosis (MS).

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsMultiple Sclerosis
CountriesUnited Kingdom
Collaborators--

Timeline

Phase 2CompletedFinished
20132014201520162017201820192020202120222023202420252026
First PostedMay 25, 2012
Enrollment StartJan 1, 2013
Primary CompletionAug 1, 2019
TodayJul 2, 2026
Enrollment to primary: 6.6 yearsPosted 14.1 years ago

Interventions

Mesenchymal stem cellsdrug

1.0-2.0 million cells/kg body weight

Placebodrug

Placebo